Search

Peptide

Reference library

Educational peptide reference — research use only.

Research & educational use only

For laboratory and educational research only. Not for human or veterinary consumption. This is not medical advice. Always follow applicable laws and consult qualified professionals.

The calculator performs unit math for research reference. It must not be used to plan or guide dosing in humans or animals. Verify all figures independently in your lab protocol.

IGF-1 LR3

A modified insulin-like growth factor studied in muscle and metabolic research.

Half-life (approx.)
~2–3 h (approx., subQ)
Diluent
Bacteriostatic water or dilute acetic acid (per published formulation data)
Common vials
0.1, 1 mg

Half-life figures are literature approximations for educational reference — not pharmacokinetic advice.

Overview

IGF-1 LR3 is an arginine-substituted IGF-1 variant with reduced binding protein affinity and extended half-life in muscle-research models. Low milligram vials require precise reconstitution math — verify concentration carefully in your calculator. Research-modified IGF-1 with reduced IGFBP binding — catalog groups native IGF-1 under this LR3 entry.

Structure & identity

IGF-1 with Arg³ substitution and 13 aa N-extension (83 aa total)

Sequence / structure
IGF-1 with Arg³ substitution and 13 aa N-extension (83 aa total)

Status: LR3 is a research-modified analog; distinct from endogenous IGF-1.

Mechanism

LR3 is a research-modified analog; distinct from endogenous IGF-1.

IGF-1 variant with reduced IGFBP binding and extended half-life for muscle-research models. Extended half-life and local muscle anabolism are primary preclinical differentiation points.

Studies & clinical programs

  • Muscle hypertrophy rodent models

    Published research models

    • Peer-reviewed literature documents endpoints under Muscle hypertrophy rodent models experimental designs.
  • L6 myotube glucose uptake

    Published research models

    • Peer-reviewed literature documents endpoints under L6 myotube glucose uptake experimental designs.

Research models in literature

  • Muscle hypertrophy rodent models
  • L6 myotube glucose uptake

Literature highlights

  • Arg³ substitution and N-terminal extension reduce IGFBP binding in muscle-hypertrophy models.
  • L6 myotube glucose-uptake and protein-synthesis endpoints in metabolic research.
  • Research-modified analog with longer half-life than endogenous IGF-1 in PK studies.

Combination research notes

Master list groups native IGF-1 and LR3 variant — LR3 is the modified research form; native IGF-1 has shorter half-life and full IGFBP binding.

Key targets & pathways

IGF-1 receptorIGFBP-3 evasionMuscle protein synthesis

Research areas

IGF-1 signalingMuscle anabolismLow-dose reconstitution

Routes in research literature

Subcutaneous

Also known as

IGF-1Long R3 IGF-1IGF-1 / IGF-1 LR3IGF 1IGF-1 LR3

Handling cautions

  • Very low mg vials — precision reconstitution required

Stability & storage phases

PhaseConditionGuidance
LyophilizedRefrigerated (2–8 °C); do not shake vialRecombinant proteins and glycoproteins require gentle handling; inspect cake integrity and store upright per IU potency literature.
ReconstitutedManufacturer diluent or bacteriostatic water, refrigeratedSwirl gently until dissolved — never shake vigorously; refrigerated stability is often shorter than small peptides (days to ~2 weeks).
Working aliquotsFrozen (−20 °C) in protein-grade tubesAliquot by IU or mg immediately after reconstitution; label concentration and avoid foam formation during draw.

Stability windows are formulation-dependent — verify published data and your lab SOP.

Reconstitution reference table

Vial (mg)Diluent (mL)mcg/mLUnits @ 100 mcgUnits @ 250 mcgUnits @ 500 mcg
0.11100.0100250500
111000.0102550

U-100 insulin syringe scale (100 units = 1 mL). Illustrative only — not dosing guidance.

Reconstitution steps

  1. Allow vial to reach room temperature (15–30 min)
  2. Swab rubber stopper with alcohol prep pad
  3. Draw calculated bacteriostatic water into syringe
  4. Inject diluent slowly down vial wall — do not spray directly onto cake
  5. Gently swirl until fully dissolved — do not shake vigorously
  6. Label with date, concentration, and diluent volume
  7. Refrigerate and use within your lab stability window

Low mg vials common; use precise diluent volume per protocol.

Laboratory record checklist

  • Compound identity recorded in lab notebook (name, lot, preparation date)
  • Analytical identity cross-checked against published sequence or structure
  • Potency or concentration documented from analytical certificate when available
  • Purity or HPLC data filed when provided with research material
  • Appearance noted: intact lyophilized cake or uniform powder
  • Sterility / endotoxin report archived when available
  • Storage temperature applied immediately per published stability guidance